{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:36:58Z","timestamp":1761871018480,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.clml.2017.07.010","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T15:18:49Z","timestamp":1501600729000},"page":"e63-e64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vascular Adverse Events During Long-term Nilotinib Therapy in Patients With Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9568-0894","authenticated-orcid":false,"given":"Ahmet Emre","family":"Eskazan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.07.010_bib1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4274\/Tjh.2013.0151","article-title":"Turkish chronic myeloid leukemia study: retrospective sectional analysis of CML patients","volume":"30","author":"Sahin","year":"2013","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.clml.2017.07.010_bib2","first-page":"353","article-title":"Adverse events of tyrosine kinase inhibitors and their impact on quality of life in patients with chronic myeloid leukemia","volume":"1","author":"Kirkizlar","year":"2016","journal-title":"Exp Rev Qual Life Cancer Care"},{"key":"10.1016\/j.clml.2017.07.010_bib3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s12529-012-9242-5","volume":"19","author":"Perk","year":"2012","journal-title":"Int J Behav Med"},{"issue":"25 suppl 2","key":"10.1016\/j.clml.2017.07.010_bib4","first-page":"S49","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.clml.2017.07.010_bib5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00277-014-2231-9","article-title":"Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment","volume":"94","author":"Breccia","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2017.07.010_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.leukres.2017.05.008","article-title":"Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML","volume":"59","author":"Valent","year":"2017","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2017.07.010_bib7","doi-asserted-by":"crossref","unstructured":"Aghel N, Lipton JH, Atenafu EG, et\u00a0al. Cardiovascular events after exposure to nilotinib in chronic myeloid leukemia: long term follow up [e-pub ahead of print]. Clin Lymphoma Myeloma Leuk. http:\/\/dx.doi.org\/10.1016\/j.clml.2017.07.006.","DOI":"10.1016\/j.clml.2017.07.006"},{"key":"10.1016\/j.clml.2017.07.010_bib8","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.07.010_bib9","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1182\/blood.V124.21.1804.1804","article-title":"The use of statin enhances chance of achieving MR4.5 in chronic myeloid leukemia patients in chronic phase following imatinib therapy","volume":"124","author":"Kim","year":"2014","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017309837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017309837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:29:32Z","timestamp":1761870572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017309837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":9,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S2152265017309837"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.07.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vascular Adverse Events During Long-term Nilotinib Therapy in Patients With Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}